Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7498482 | 0.82 | GALR3 (0.50) | PTAFRGALR3NR2F2RAB9ATNF | |
| SCHEMBL3969688 | 0.82 | TNF (0.70) | PTAFRDCTPP1GALR3NR2F2RAB9A | |
| SCHEMBL9049974 | 0.82 | GALR3 (0.50) | PTAFRGALR3NR2F2RAB9ATNF | |
| SCHEMBL7497522 | 0.82 | GALR3 (0.68) | PTAFRGALR3NR2F2RAB9ATNF | |
| SCHEMBL9051695 | 0.82 | GALR3 (0.50) | PTAFRGALR3NR2F2RAB9ATNF | |
| SCHEMBL9051522 | 0.82 | GALR3 (0.52) | PTAFRBRD4GALR3NR2F2RAB9A | |
| Bromide SCHEMBL9054549 | 0.81 | GALR3 (0.49) | PTAFRGALR3NR2F2RAB9ATNF | |
| Bromide SCHEMBL9052476 | 0.81 | GALR3 (0.51) | PTAFRBRD4GALR3NR2F2RAB9A | |
| SCHEMBL7496365 | 0.81 | — | — | |
| SCHEMBL9051629 | 0.81 | PTAFR (0.50) | PTAFRGALR3NR2F2RAB9ATNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996033997-A1 | BENZIMIDAZOLE DERIVATIVES BEING DUAL HISTAMINE (H1) AND PLATELET ACTIVATING FACTOR (PAF) ANTAGONISTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |